Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials

Researchers find that the antidepressant vortioxetine may offer new hope for glioblastoma patients by crossing the blood-brain barrier and significantly reducing tumor size in preclinical models.

Study: High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Image Credit: Elif Bayraktar / Shutterstock.com

A recent Nature Medicine study evaluates the potential to repurpose currently approved drugs to treat cancer and neurological disorders for their therapeutic effects against glioblastoma.  

Current treatment strategies for glioblastoma

Glioblastoma is an incurable and fatal type of brain cancer, with about 50% of patients dying within twelve months of diagnosis. The life expectancy of glioblastoma patients can be extended through radiation, chemotherapy, or surgical interventions.

Many drugs that are used to treat cancer cannot cross the blood-brain barrier (BBB), thus limiting the utility of these agents in treating brain tumors like glioblastoma. Targeted therapies have been associated with limited success in the treatment of glioblastoma due to the lack of clinically predictive patient model systems, as well as the presence of treatment-resistant glioblastoma stem cells (GSCs).

Recent studies investigating the pathophysiology of glioblastoma have reported synaptic integration of cancer cells into neural circuits, stemness signatures resembling neural development, and the modulation of specific neurotransmitter pathways in the tumor microenvironment (TME). These characteristics may reflect vulnerabilities of glioblastoma cells, which may be therapeutically relevant, particularly when investigating the potential repurposing of existing ‘neuroactive’ drugs (NADs).

The lack of effective treatments for managing glioblastoma emphasizes the importance of identifying neurotherapeutic vulnerabilities that can guide future drug discovery in this field. To date, the anti-cancer activity of most NADs has not been evaluated for the treatment of glioblastoma.

About the study

Pharmacoscopy is an ex vivo image-based drug screening approach that has been validated in functional precision medical trials assessing the effects of novel agents in the treatment of hematological malignancies. In the current study, researchers used pharmacoscopy to simultaneously test the in vitro and in vivo efficacy of both neuroactive and oncology drug (ONCD) libraries against glioblastoma patient samples.

The neuroactive drug library consisted of drugs capable of crossing the BBB that are currently approved for the treatment of neurological diseases like Alzheimer’s disease, depression, and schizophrenia. Comparatively, the ONCD drug library consisted of conventional cancer treatments, such as cyclin-dependent kinase (CDK) and receptor tyrosine kinase (RTK) inhibitors.

A total of 130 different agents were used to treat tumor tissues isolated from 27 patients who recently underwent surgery at the University Hospital Zurich. Imaging techniques and computer analysis were used to identify drugs that influenced cancer cells.

Study findings

Several ONCDs were capable of penetrating the BBB, which included elesclomol, osimertinib, and regorafenib.

Certain patient characteristics increased the sensitivity of their tumor cells to specific ONCDs. For example, age was associated with greater sensitivity to elesclomol, tumor samples obtained from patients with TP53 mutations were more sensitive to CDK4/6 inhibitor abemaciclib, and patients with the loss of rearranged during transfection (RET) copies were more sensitive to pazopanib.

Fifteen NADs exhibited anti-glioblastoma activity, with vortioxetine, an antidepressant, inducing significant ex vivo efficacy in about 67% of patient samples. Other potent NADs were paroxetine, fluoxetine, and brexpiprazole.

Higher sertindole sensitivity was observed among patients with fibroblast growth factor receptor 2 (FGFR2) copy number loss. Moreover, higher ex vivo sensitivity to brexpiprazole was observed in male patients.

A machine learning approach was designed to search for the convergence of secondary drug targets analyzed by regularized regression (COSTAR). This model tested over one million substances for their effectiveness against glioblastoma and documented neuroactive convergence on activating protein 1 (AP-1)/BTG-driven glioblastoma suppression. The joint signaling cascade of cancer and neural cells is important and key to elucidating the selective therapeutic efficacy of certain NADs.

Vortioxetine was consistently the most effective NAD in vivo, especially in combination with the current standard treatment. Furthermore, the survival benefits associated with vortioxetine treatment were significant and similar to those of alkylating agent temozolomide (TMZ).

Magnetic resonance imaging (MRI) scans of transplanted mice showed a significant reduction in tumor size post-treatment with vortioxetine. In vitro, vortioxetine reduced glioblastoma growth, clonogenic survival, and invasiveness.

Consistent with previously reported findings, paliperidone and citalopram were not associated with any survival benefit. The ineffectiveness of citalopram suggests that anti-glioblastoma efficacy is not conferred solely by serotonin modulation.

Conclusions

Diverse NADs, particularly the antidepressant vortioxetine, led to rapid glioblastoma cell death.

Although the study findings are promising, vortioxetine should not be used in the treatment of glioblastoma without proper medical supervision, as its efficacy has only been proven in vitro and in mice. Thus, future clinical studies are needed to evaluate the therapeutic efficacy of vortioxetine in human glioblastoma patients.

Journal reference:
  • Lee, S., Weiss, T., Buhler, M., et al. (2024) High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nature Medicine; 1-13. doi:10.1038/s41591-024-03224-y
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2024, September 24). Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials. News-Medical. Retrieved on October 05, 2024 from https://www.news-medical.net/news/20240924/Neuroactive-drugs-show-promising-anti-glioblastoma-effects-in-preclinical-trials.aspx.

  • MLA

    Bose, Priyom. "Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials". News-Medical. 05 October 2024. <https://www.news-medical.net/news/20240924/Neuroactive-drugs-show-promising-anti-glioblastoma-effects-in-preclinical-trials.aspx>.

  • Chicago

    Bose, Priyom. "Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials". News-Medical. https://www.news-medical.net/news/20240924/Neuroactive-drugs-show-promising-anti-glioblastoma-effects-in-preclinical-trials.aspx. (accessed October 05, 2024).

  • Harvard

    Bose, Priyom. 2024. Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials. News-Medical, viewed 05 October 2024, https://www.news-medical.net/news/20240924/Neuroactive-drugs-show-promising-anti-glioblastoma-effects-in-preclinical-trials.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.